Ibrutinib Addition Fails To RESOLVE Metastatic Pancreatic Cancer
Metastatic pancreatic cancer patients do not gain a survival benefit from the use of ibrutinib alongside first-line chemotherapy
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Metastatic pancreatic cancer patients do not gain a survival benefit from the use of ibrutinib alongside first-line chemotherapy
Metastatic non-small-cell lung cancer patients with a PD-L1 TPS score of 50% or higher do not benefit from use of ipilimumab alongside first-line pembrolizumab
For advanced non-small-cell lung cancer patients, overall survival is improved when first-line nivolumab plus ipilimumab is supplemented with two cycles of chemotherapy
From the World Conference on Lung Cancer 2022:
Lead-in sotorasib monotherapy followed by the addition of pembrolizumab has shown early promise for the treatment of advanced KRAS G12C-mutated NSCLC
From ASCO 2022 Annual Meeting:
Preliminary findings indicate that patients with tumours harbouring NRG1 fusions may benefit from treatment with zenocutuzumab or seribantumab
From ASCO 2022 Annual Meeting:
Amivantamab shows activity in NSCLC patients with a primary MET exon 14 skipping mutation and when used in combination with lazertinib for those with EGFR mutations who have progressed after osimertinib and chemotherapy
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.